SCHEDULE 13G/A: EcoR1 Capital and Affiliates Disclose 1.3% Stake in TScan Therapeutics

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an amended Schedule 13G, disclosing their beneficial ownership of 1.3% of TScan Therapeutics, Inc.'s Voting Common Stock as of March 31, 2025.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in TScan Therapeutics, Inc.
• As of March 31, 2025, EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 662,833 shares of TScan Therapeutics' Voting Common Stock.
• This ownership represents 1.3% of the total class of securities.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 623,967 shares, representing 1.2% of the class.
• The percentages are calculated based on 52,314,039 shares of Voting Common Stock outstanding on February 28, 2025, as reported in TScan Therapeutics' Form 10-K for the fiscal year ended December 31, 2024.
• All reported shares are held with shared voting and shared dispositive power among the reporting persons.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, factual disclosure of beneficial ownership as required by SEC regulations. This filing does not contain performance data or forward-looking statements that would influence sentiment.

Future Outlook

NA

Industry Context

NA

Key Dates

Keywords

TScan Therapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, SEC Filing, Voting Common Stock, Investment Adviser, Biotechnology